Skip to content
Clinical Trials – home
Therapeutic area

Congenital, familial and genetic disorders – page 11

  • 803 clinical trials
  • 311 recruiting
  • 375 conditions
  • 27 countries

Conditions in this area

375 conditions with trials, the busiest first

Clinical trials in Congenital, familial and genetic disorders

803 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

803 clinical trials

Study on Testosterone and Isopropyl Myristate for Women with Turner Syndrome

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Carbomer 980
  • Sponsor:Region Midtjylland

Study of glycerol phenylbutyrate (oral liquid) for treatment of fatigue in patients with pyruvate dehydrogenase deficiency

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Glycerol Phenylbutyrate
  • Sponsor:Assistance Publique Hopitaux De Paris

Long-term Safety and Efficacy Study of Etuvetidigene Autotemcel for Patients with Wiskott-Aldrich Syndrome

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Etuvetidigene Autotemcel
  • Sponsor:Fondazione Telethon Ets

Study on the Effectiveness and Safety of Sepofarsen for Patients with Leber Congenital Amaurosis Due to a Specific Genetic Mutation

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sepofarsen
  • Sponsor:Laboratoires Thea

Study on Inclisiran, Alirocumab, and Rosuvastatin for Children with Familial Hypercholesterolemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Alirocumab
  • Sponsor:Medical University Of Lodz

Study on the Safety and Effectiveness of CRN04894 for Patients with Congenital Adrenal Hyperplasia

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Study of N-Acetyl-L-Leucine in Patients with Ataxia-Telangiectasia: A Phase III Trial

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:L-Acetylleucine
  • Sponsor:Intrabio Limited

Study on the Effects of TCP-25 Gel for Wound Healing in Patients with Epidermolysis Bullosa

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:H-GLY-LYS-TYR-GLY-PHE-TYR-THR-HIS-VAL-PHE-ARG-LEU-LYS-LYS-TRP-ILE-GLN-LYS-VAL-ILE-ASP-GLN-PHE-GLY-GLU-OH
  • Sponsor:Xinnate AB

Study on Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa Using Skin Grafts with Genetically Corrected Autologous Keratinocytes and Fibroblasts

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AUTOLOGOUS KERATINOCYTES AND FIBROBLASTS TRANSDUCED WITH A RETROVIRAL VECTOR ENCODING COL7A1 CDNA
  • Sponsor:Inserm

Study of SGT-003 Gene Therapy for Safety and Tolerability in Walking Males with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:SGT-003
  • Sponsor:Solid Biosciences Inc.

Study on the Effects of Pitolisant Hydrochloride for Patients with Prader-Willi Syndrome

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Harmony Biosciences LLC

Study on the Safety and Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Adults with Severe or Moderately Severe Hemophilia B and AAV5 Antibodies

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Etranacogene Dezaparvovec
  • Sponsor:CSL Behring LLC

Substances studied in this area

The therapies tested most often in Congenital, familial and genetic disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.